<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591887</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-035-002</org_study_id>
    <secondary_id>2017-001615-36</secondary_id>
    <nct_id>NCT03591887</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis</brief_title>
  <acronym>AFFIRM-35</acronym>
  <official_title>A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Affibody</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in
      comparison to placebo, in subjects with moderate to severe plaque psoriasis.

      The study consists of a four week screening period, three treatment periods of a total of 48
      weeks, and a four-week follow-up period.

      The subjects are randomized to one out of four dose levels, or placebo (1:1:1:1:1). After the
      first 12 weeks of treatment, the subjects randomized to placebo will receive active
      treatment. The dose levels and dosing intervals are adjusted depending on the absolute PASI
      score, to obtain an individualized treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with
      moderate to severe plaque psoriasis.

      The study consists of a four week screening period, three treatment periods and a four-week
      follow-up period.

      The treatment periods are:

        1. Randomized treatment; four dose levels and placebo. Biweekly (Q2W) administration during
           during 12 weeks.

        2. Administration Q2W during during 12 weeks, starting with a possible dose adjustment
           depending on the achieved absolute PASI score. Subjects on placebo are switched to
           active drug every 4 weeks (Q4W).

        3. Administration Q4W, starting with a possible dose adjustment , depending on the achieved
           absolute PASI score. The dosing interval is varied between Q4W and Q8W, depending on the
           PASI score.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Actual">April 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a ≥90% improvement in Psoriasis Area and Severity Index (PASI90) at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PASI combines the extent of body surface involvement in the body regions head, trunk, arms, and legs. The percent area of the skin involved is estimated per region (0-100%). The severity is estimated by clinical signs of erythema, induration and scaling, from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). PASI90 is a ≥90% reduction from Baseline in PASI score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Adverse Events judged by the investigator to be related to study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a ≥90% improvement in PASI (PASI90) at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>A ≥90% reduction from Baseline in PASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a ≥90% improvement in PASI (PASI90) at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>A ≥90% reduction from Baseline in PASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a ≥75% improvement in PASI (PASI75) at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>A ≥75% reduction from Baseline in PASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a 100% improvement in PASI (PASI100) at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>A 100% reduction from Baseline in PASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an absolute PASI score ≤1 at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>PASI ≤1 equals clear or almost clear skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an absolute PASI score ≤1 at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>PASI ≤1 equals clear or almost clear skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an absolute PASI score ≤1 at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>PASI ≤1 equals clear or almost clear skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Static Physician's Global Assessment (sPGA) 1 or 0 at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The sPGA is the physician's determination of the subject's Psoriasis lesions overall at a given time point, with the grading 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Dermatology Life Quality Index (DLQI) of 0 or 1 at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>DLQI is a 10-question quality-of-life questionnaire completed by the subject. It covers 6 the domains symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The total scores range from 0 to 30, with higher score indicating greater quality of life impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with DLQI of 0 or 1 at week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>DLQI: Dermatology Life Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with DLQI of 0 or 1 at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>DLQI: Dermatology Life Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in target nail Nail Psoriasis Severity Index (NAPSI) at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The NAPSI scale is used to evaluate the severity of psoriasis in the fingernail bed and matrix. The nail is divided into quadrants. Each quadrant is given the score 0 (absence) or 1 (presence) for psoriasis in the beds and matrix, respectively. The NAPSI score of a nail is the sum of each quadrant. The maximum score per nail is 8.
In the target nail NAPSI, the worst affected nail at Baseline is evaluated throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pain-Visual Analogue Scale (VAS) at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Pain-VAS: A patient measurement of level pain, from 0 (no pain) to 100 (worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in itch-Visual Analogue Scale (VAS) at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Itch-VAS: A patient measurement of level itching from 0 (no itch) to 100 (worst possible itch)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve (AUC) of ABY-035</measure>
    <time_frame>Week 12</time_frame>
    <description>AUC is a measure of the drug exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of anti-ABY-035 antibodies in serum</measure>
    <time_frame>Week 52</time_frame>
    <description>Anti-drug antibodies</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>ABY-035 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg ABY-035 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABY-035 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg ABY-035 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABY-035 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg ABY-035 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABY-035 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mg ABY-035 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, switching to 80 mg ABY-035 after 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABY-035</intervention_name>
    <description>ABY-035 solution for injection</description>
    <arm_group_label>ABY-035 160 mg</arm_group_label>
    <arm_group_label>ABY-035 2 mg</arm_group_label>
    <arm_group_label>ABY-035 20 mg</arm_group_label>
    <arm_group_label>ABY-035 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to ABY-035 solution for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with plaque psoriasis of at least 6 months prior to Screening, without
             clinically significant flares during the 12 weeks before randomization, with or
             without psoriatic arthritis

          -  Having precedent failure, intolerance or contraindication to at least two standard
             therapies for moderate-to-severe plaque psoriasis

          -  Moderate-to-severe plaque psoriasis at Screening and at Baseline as defined by:

             i. Psoriasis involving ≥10% BSA ii. PASI score of ≥ 12 iii. sPGA score of ≥ 3

          -  Use of highly effective contraceptive measure, female of non-childbearing potential or
             sterilized male

        Exclusion Criteria:

          -  Current forms of psoriasis other than chronic plaque-type

          -  Current drug induced psoriasis

          -  History of recurrent or medically important infections requiring intervention and/or
             systemic treatment in the last 12 months, including infections with e.g. candida and
             Staphylococcus aureus

          -  Autoimmune disease of relevance

          -  Inflammatory Bowel Disease requiring treatment within the past 12 months

          -  Significantly immunocompromised subject

          -  Blood pressure out of range

          -  Laboratory values out of range, including ALT, AST, eGFR

          -  Positive to HIV, hepatitis B, hepatitis C or tuberculosis

          -  Numerous recent previous psoriasis treatments ,with defined wash-out periods

          -  Prior exposure to systemic psoriasis treatments with anti-IL-17 biological therapies

          -  Live vaccination within defined time restrictions

          -  Inability or unwillingness to limit ultraviolet (UV) light exposure during the course
             of the study

          -  Pregnancy, breast feeding

          -  Drug and/or alcohol abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sascha Gerdes, Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Dermatologie, Venerologie und Allergologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rothhaar Studien GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10783</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Haut- und Geschlechtskrankheiten im Ärztehaus &quot;Rudolf Virchow&quot;</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum Weissensee</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztzentrum Tegel</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie der Ruhr-Universität</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis im Jahrhunderthaus</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RuhrDerm - Studienzentrum der Gemeinschaftspraxis für Dermatologie, Venerologie, Allergologie, Phlebologie</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elbe Kliniken Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <zip>21615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenpark Research</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatpraxis Dr. Hilton &amp; Partner</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma-Study-Center FN GmbH</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCIderm Clinics</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologische Gemeinschaftspraxis</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical research center (CRC) Department of Dermatology</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. Unnewehr</name>
      <address>
        <city>Osnabrück</city>
        <zip>49078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMS³ - Company for Medical Study &amp; Service Selters UG</name>
      <address>
        <city>Selters</city>
        <zip>56242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentroDerm GmbH</name>
      <address>
        <city>Wuppertal</city>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

